Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. World J Gastroenterol 2018; 24(48): 5418-5432 [PMID: 30622371 DOI: 10.3748/wjg.v24.i48.5418]
Corresponding Author of This Article
Michael Linnebacher, PhD, Academic Fellow, Department of General Surgery, Section of Molecular Oncology and Immunotherapy, University Medical Center, Schillingallee 35, Rostock D-18057, Germany. michael.linnebacher@med.uni-rostock.de
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Dec 28, 2018; 24(48): 5418-5432 Published online Dec 28, 2018. doi: 10.3748/wjg.v24.i48.5418
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens
Sandra Wagner, Christina S Mullins, Michael Linnebacher
Sandra Wagner, Christina S Mullins, Michael Linnebacher, Section of Molecular Oncology and Immunotherapy, General Surgery, University Medical Center, Rostock D-18057, Germany
Author contributions: Wagner S and Linnebacher M wrote the manuscript and critically reviewed the final version of the manuscript. Mullins CS was involved in the design of the figures; critically reviewed the revised manuscript and language edited the manuscript as a native speaker.
Supported byMinisterium für Wirtschaft, Arbeit und Gesundheit Mecklenburg-Vorpommern, No. TBI-V-1-241-VBW-084.
Conflict-of-interest statement: Ms. Wagner has nothing to disclose. Dr. Mullins is supported by the Robert Bosch Stiftung with a Fast Track scholarship. Dr. Linnebacher reports grants from Ministerium für Wirtschaft, Arbeit und Gesundheit Mecklenburg-Vorpommern, during the conduct of the study.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Michael Linnebacher, PhD, Academic Fellow, Department of General Surgery, Section of Molecular Oncology and Immunotherapy, University Medical Center, Schillingallee 35, Rostock D-18057, Germany. michael.linnebacher@med.uni-rostock.de
Telephone: +49-381-4946043 Fax: +49-381-4946002
Received: October 13, 2018 Peer-review started: October 14, 2018 First decision: November 8, 2018 Revised: December 11, 2018 Accepted: December 20, 2018 Article in press: December 21, 2018 Published online: December 28, 2018 Processing time: 75 Days and 20.1 Hours
Core Tip
Core tip: Peptide vaccines are a promising tool for colorectal cancer (CRC) treatment. Direct comparison of tumor-associated antigens (TAAs) and neoantigens reveals clear superiority of the latter for several reasons. TAAs, albeit easier to identify and even shared by many patients, did not prove effective in clinical trials. Additionally, and due to their unspecificity, they frequently trigger severe adverse events. This risk is neglectable for tumor-specific neoantigens - thus compensating for the costly and laborious identification of such antigens expressed in individual patient tumors. Intelligent modern CRC vaccines will likely combine several or even many individual neoantigen-derived peptides with immuno-chemotherapy, adjuvants or further immuno-modulators.
